enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Hypoglossal nerve stimulator - Wikipedia

   en.wikipedia.org/wiki/Hypoglossal_nerve_stimulator

   The implant may be configured to best accommodate the patient's comfort and sleeping habits (e.g., set a delay based on sleep latency). The hypoglossal nerve stimulator implantable pulse generator battery life typically lasts 8–12 years, after which the implantable pulse generator may be safely replaced with another surgery. [8]

3. CPAP replacement works well for the overweight, not obese ...

   www.aol.com/implantable-alternative-cpap...

   To qualify for the device, called a hypoglossal nerve stimulator, a person over 18 diagnosed with moderate-to-severe obstructive sleep apnea must be unable to adapt or refuse to wear a continuous ...

4. Does Medicare cover Inspire treatment for sleep apnea? - AOL

   www.aol.com/does-medicare-cover-inspire...

   Inspire is a hypoglossal nerve stimulator (HNS) to treat obstructive sleep apnea. ... to treat obstructive sleep apnea. It is an implantable device that stimulates nerves controlling the tongue ...

5. New tongue implant offers hope to millions of British snorers ...

   www.aol.com/news/tongue-implant-offers-hope...

   Both devices stimulate the hypoglossal nerve, which controls the muscles in the tongue, and can be an alternative to continuous positive airway pressure (Cpap) machines.

6. Neuromodulation (medicine) - Wikipedia

   en.wikipedia.org/wiki/Neuromodulation_(medicine)

   Hypoglossal nerve stimulation, an option for some patients who have obstructive sleep apnea [28] Percutaneous tibial nerve stimulation (PTNS) for the treatment of incontinence. Peripheral nerve stimulation (PNS, which refers to simulation of nerves beyond the spine or brain, and may be considered to include occipital or sacral nerve stimulation)

7. Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U ...

   lite.aol.com/tech/story/0022/20240902/1000989628.htm

   Announcement of positive data from the pivotal U.S. study, DREAM, regarding Nyxoah’s Genio® system, an innovative hypoglossal neurostimulation therapy for Obstructive Sleep Apnea (OSA) in spring 2024. Final module submitted in the modular PMA submission, initiating FDA interactive review.